[EN] TSH-CONJUGATED NANOCARRIER FOR THE TREATMENT OF THYROID CANCER<br/>[FR] NANOVECTEUR CONJUGUÉ AU TSH POUR LE TRAITEMENT DU CANCER DE LA THYROÏDE
申请人:UNI DEGLI STUDI MAGNA GRAECIA DI CATANZARO
公开号:WO2012073125A1
公开(公告)日:2012-06-07
The present invention provides a liposome comprising a PEG-PDP-TSH component, in particular a) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine monohydrate, b) cholesterol, c) 1,2- distearoyl-sn-glycero-3-phosphoethanolamine and d) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(methoxypolyethylene glycol-2000)].Preferably, the liposome is in the form of small unilamellar vesicle and has nanometric size. The liposome of the invention can be loaded with at least one drug suitable for the treatment of a thyroid disease, in particular gemcitabine, and is suitable for the intracellular delivery of a substance to a cell expressing TSHR.Said liposome can be used for the preparation of a medicament for the treatment of a disease of thyroid gland, in particular thyroid neoplasia. The present invention also provides a pharmaceutical composition comprising the liposome, in particular for intravenous administration.